The Pathogenesis and Management of Acne-Induced Post-inflammatory Hyperpigmentation.
Acne Vulgaris
/ complications
Anti-Inflammatory Agents
/ therapeutic use
Combined Modality Therapy
/ methods
Dermabrasion
/ methods
Dermatologic Agents
/ therapeutic use
Humans
Hyperpigmentation
/ immunology
Low-Level Light Therapy
/ instrumentation
Melanins
/ antagonists & inhibitors
Skin
/ immunology
Skin Pigmentation
/ drug effects
Journal
American journal of clinical dermatology
ISSN: 1179-1888
Titre abrégé: Am J Clin Dermatol
Pays: New Zealand
ID NLM: 100895290
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
accepted:
02
08
2021
pubmed:
2
9
2021
medline:
19
2
2022
entrez:
1
9
2021
Statut:
ppublish
Résumé
Acne vulgaris is a common inflammatory disease. Among patients with darker skin phototypes (Fitzpatrick III-VI), the inflammatory processes of acne stimulate excess melanogenesis and abnormal melanin deposition, leading to pigmentary sequelae known as post-inflammatory hyperpigmentation and post-inflammatory erythema in all skin tones, although post-inflammatory hyperpigmentation is more common in darker skin and post-inflammatory erythema in lighter skin. These pigmentary alterations can be long lasting and are often more distressing to patients than the active acne lesions. This article discusses what is known about acne-related pigmentation, much of which is extrapolated from general study of nonspecific pigment deposition. Because dyspigmentation poses both a significant clinical concern to patients and a therapeutic challenge to clinicians, we formed a working group consisting of pigmentary experts with the aim of increasing awareness and education of acne-related pigmentary sequelae.
Identifiants
pubmed: 34468934
doi: 10.1007/s40257-021-00633-4
pii: 10.1007/s40257-021-00633-4
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Dermatologic Agents
0
Melanins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
829-836Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Alexis AF, Lamb A. Concomitant therapy for acne in patients with skin of color: a case-based approach. Dermatol Nurs. 2009;21:33–6.
pubmed: 19283960
Halder RM, Brooks HL, Callender VD. Acne in ethnic skin. Dermatol Clin. 2003;21(609–15):vii.
Halder RM, Grimes PE, McLaurin CI, Kress MA, Kenney JA Jr. Incidence of common dermatoses in a predominantly black dermatologic practice. Cutis. 1983;32(388):390.
Taylor SC. Epidemiology of skin diseases in ethnic populations. Dermatol Clin. 2003;21:601–7.
pubmed: 14717401
doi: 10.1016/S0733-8635(03)00075-5
Abad-Casintahan F, Chow SK, Goh CL, et al. Frequency and characteristics of acne-related post-inflammatory hyperpigmentation. J Dermatol. 2016;43(7):926–8.
doi: 10.1111/1346-8138.13263
Goh CL, Abad-Casintahan F, Chow SK, et al. Evaluating acne-related post-inflammatory hyperpigmentation is a challenge even amongst experts. J Dermatol. 2014;41:1106–8.
pubmed: 25327447
doi: 10.1111/1346-8138.12667
Gollnick H, Abanmi AA, Al-Enezi M, et al. Managing acne in the Middle East: consensus recommendations. J Eur Acad Dermatol Venereol. 2017;31(Suppl. 7):4–35.
pubmed: 28990222
doi: 10.1111/jdv.14491
Abanmi AA, Al-Enezi M, Al Hammadi A, Galadari I, Kibbi A-G, Zimmo S. Progress and problems with acne management in the Middle East. Gulf J Dermatol Venereol. 2016;23:1–5.
Callender VD, Barbosa V, Burgess CM, et al. Approach to treatment of medical and cosmetic facial concerns in skin of color patients. Cutis. 2017;100:375–80.
pubmed: 29360898
Kang SJ, Davis SA, Feldman SR, McMichael AJ. Dyschromia in skin of color. J Drugs Dermatol. 2014;13:401–6.
pubmed: 24719058
Davis SA, Narahari S, Feldman SR, Huang W, Pichardo-Geisinger RO, McMichael AJ. Top dermatologic conditions in patients of color: an analysis of nationally representative data. J Drugs Dermatol. 2012;11:466–73.
pubmed: 22453583
Min S, Park SY, Yoon JY, Kwon HH, Suh DH. Fractional microneedling radiofrequency treatment for acne-related post-inflammatory erythema. Acta Derm Venereol. 2016;96:87–91.
pubmed: 26059315
doi: 10.2340/00015555-2164
Tan J, Bourdes V, Bissonnette R, et al. Prospective study of pathogenesis of atrophic acne scars and role of macular erythema. J Drugs Dermatol. 2017;16:566–72.
pubmed: 28686774
Poli F. Acne on pigmented skin. Int J Dermatol. 2007;46(Suppl. 1):39–41.
pubmed: 17919206
doi: 10.1111/j.1365-4632.2007.03463.x
Akinboro AO, Ezejiofor OI, Olanrewaju FO, et al. The impact of acne and facial post-inflammatory hyperpigmentation on quality of life and self-esteem of newly admitted Nigerian undergraduates. Clin Cosmet Investig Dermatol. 2018;11:245–52.
pubmed: 29785134
pmcid: 5955012
doi: 10.2147/CCID.S158129
Abanmi A, Al-Enezi M, Al Hammadi A, Galadari I, Kibbi AG, Zimmo S. Survey of acne-related post-inflammatory hyperpigmentation in the Middle East. J Dermatolog Treat. 2019;30:578–81.
pubmed: 30426810
doi: 10.1080/09546634.2018.1542807
Layton AM, Henderson CA, Cunliffe WJ. A clinical evaluation of acne scarring and its incidence. Clin Exp Dermatol. 1994;19:303–8.
pubmed: 7955470
doi: 10.1111/j.1365-2230.1994.tb01200.x
Kane A, Niang SO, Diagne AC, Ly F, Ndiaye B. Epidemiologic, clinical, and therapeutic features of acne in Dakar. Senegal Int J Dermatol. 2007;46(Suppl. 1):36–8.
pubmed: 17919205
doi: 10.1111/j.1365-4632.2007.03462.x
Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3:20–31.
pubmed: 20725554
pmcid: 2921758
Tanghetti EA. The role of inflammation in the pathology of acne. J Clin Aesthet Dermatol. 2013;6:27–35.
pubmed: 24062871
pmcid: 3780801
Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003;121:20–7.
pubmed: 12839559
doi: 10.1046/j.1523-1747.2003.12321.x
Norris JF, Cunliffe WJ. A histological and immunocytochemical study of early acne lesions. Br J Dermatol. 1988;118:651–9.
pubmed: 2969256
doi: 10.1111/j.1365-2133.1988.tb02566.x
Silpa-Archa N, Kohli I, Chaowattanapanit S, Lim HW, Hamzavi I. Postinflammatory hyperpigmentation: a comprehensive overview: epidemiology, pathogenesis, clinical presentation, and noninvasive assessment technique. J Am Acad Dermatol. 2017;77:591–605.
pubmed: 28917451
doi: 10.1016/j.jaad.2017.01.035
Adalatkhah H, Sadeghi BH. The association between melasma and postinflammatory hyperpigmentation in acne patients. Iran Red Crescent Med J. 2013;15:400–3.
pubmed: 24349727
pmcid: 3838649
doi: 10.5812/ircmj.5358
Nordlund JJB, Hearing VJ, King RA, Oetting W, Ortonne JP. The pigmentary system: physiology and pathophysiology. Malden: Blackwell Publishing; 2006.
doi: 10.1002/9780470987100
Cayce KA, McMichael AJ, Feldman SR. Hyperpigmentation: an overview of the common afflictions. Dermatol Nurs. 2004;16:401–6.
pubmed: 15624705
Isedeh P, Kohli I, Al-Jamal M, et al. An in vivo model for postinflammatory hyperpigmentation: an analysis of histological, spectroscopic, colorimetric and clinical traits. Br J Dermatol. 2016;174:862–8.
pubmed: 26663029
doi: 10.1111/bjd.14184
Nordlund JJA-M, Abdel-Malek ZA. Mechanisms for post-inflammatory hyperpigmentation and hypopigmentation. In: Bagnara JT, editor. Thirteenth international pigment. Tucson: Liss; 1986. p. 219–39.
Ebanks JP, Wickett RR, Boissy RE. Mechanisms regulating skin pigmentation: the rise and fall of complexion coloration. Int J Mol Sci. 2009;10:4066–87.
pubmed: 19865532
pmcid: 2769151
doi: 10.3390/ijms10094066
Del Bino S, Duval C, Bernerd F. Clinical and biological characterization of skin pigmentation diversity and its consequences on UV impact. Int J Mol Sci. 2018;19:2668.
pmcid: 6163216
doi: 10.3390/ijms19092668
pubmed: 6163216
Shin JWP, Park KC. Current clinical use of depigmenting agents. Dermatol Sin. 2014;32:205–10.
doi: 10.1016/j.dsi.2014.07.003
D’Mello SA, Finlay GJ, Baguley BC, Askarian-Amiri ME. Signaling pathways in melanogenesis. Int J Mol Sci. 2016;17(7):1144.
pmcid: 4964517
doi: 10.3390/ijms17071144
pubmed: 4964517
Shah SK, Alexis AF. Acne in skin of color: practical approaches to treatment. J Dermatol Treat. 2010;21:206–11.
doi: 10.3109/09546630903401496
Chaowattanapanit S, Silpa-Archa N, Kohli I, Lim HW, Hamzavi I. Postinflammatory hyperpigmentation: a comprehensive overview: treatment options and prevention. J Am Acad Dermatol. 2017;77:607–21.
pubmed: 28917452
doi: 10.1016/j.jaad.2017.01.036
Palumbo A, d’Ischia M, Misuraca G, Prota G. Mechanism of inhibition of melanogenesis by hydroquinone. Biochim Biophys Acta. 1991;1073:85–90.
pubmed: 1899343
doi: 10.1016/0304-4165(91)90186-K
Kircik LH. Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study. J Drugs Dermatol. 2011;10:586–90.
pubmed: 21637899
Sarkar R, Ghunawat S, Garg VK. Comparative study of 35% glycolic acid, 20% salicylic-10% mandelic acid, and phytic acid combination peels in the treatment of active acne and postacne pigmentation. J Cutan Aesthet Surg. 2019;12:158–63.
pubmed: 31619887
pmcid: 6785964
doi: 10.4103/JCAS.JCAS_135_18
Chan HH, Manstein D, Yu CS, Shek S, Kono T, Wei WI. The prevalence and risk factors of post-inflammatory hyperpigmentation after fractional resurfacing in Asians. Lasers Surg Med. 2007;39:381–5.
pubmed: 17518354
doi: 10.1002/lsm.20512
Alexis AF. Lasers and light-based therapies in ethnic skin: treatment options and recommendations for Fitzpatrick skin types V and VI. Br J Dermatol. 2013;169(Suppl. 3):91–7.
pubmed: 24098905
doi: 10.1111/bjd.12526
Bae YC, Rettig S, Weiss E, Bernstein L, Geronemus R. Treatment of post-inflammatory hyperpigmentation in patients with darker skin types using a low energy 1,927 nm non-ablative fractional laser: a retrospective photographic review analysis. Lasers Surg Med. 2020;52:7–12.
pubmed: 31663147
doi: 10.1002/lsm.23173
Haimovic A, Brauer JA, Cindy Bae YS, Geronemus RG. Safety of a picosecond laser with diffractive lens array (DLA) in the treatment of Fitzpatrick skin types IV to VI: a retrospective review. J Am Acad Dermatol. 2016;74:931–6.
pubmed: 26947448
doi: 10.1016/j.jaad.2015.12.010